Neuroimaging of Diseases Causing Dementia

Area of Science:

• Neuroimaging
• Neurology
• Biomedical imaging

Background:

• Neuroimaging offers insights into the biological mechanisms of dementia.
• Different dementia types exhibit distinct patterns in neuroimaging studies.

Purpose of the Study:

• To review the utility of various neuroimaging techniques in dementia diagnosis and progression monitoring.
• To highlight the role of PET and MRI in differentiating dementia subtypes.

Main Methods:

• Amyloid PET scans to detect amyloid plaques characteristic of Alzheimer's disease (AD).
• Tau PET scans to assess tau pathology, prominent in AD and present in frontotemporal dementia (FTD).
• Magnetic resonance imaging (MRI) for quantifying brain volume loss.
• Fluorodeoxyglucose (FDG) PET for measuring brain metabolism.
• Positron Emission Tomography (PET) for assessing brain inflammation.

Main Results:

• Amyloid PET is positive in AD and some Lewy body diseases, but negative in FTD.
• Tau PET shows a stronger signal in AD compared to FTD.
• MRI and FDG-PET aid in differentiating dementia causes and tracking disease progression.
• PET can assess brain inflammation, a factor in some dementias.

Conclusions:

• Neuroimaging techniques are crucial for understanding dementia's biological underpinnings.
• Current and investigational neuroimaging methods show promise for future clinical use in dementia care.
• These advanced imaging tools facilitate differential diagnosis and disease monitoring.